-
A Nurse’s Overview of First-Line Treatment for HR+ Metastatic Breast Cancer
28 Aug 2025 16:14 GMT
… , HER2-negative breast cancer comprising about 70% of breast cancer diagnoses,1 an … HR-positive, HER2-negative metastatic breast cancer include ribociclib (Kisqali), abemaciclib … include anastrozole, letrozole, and exemestane. Across the drug class, …
-
Oral SERDs and PI3K Inhibitors Move the Needle Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer
01 Aug 2025 23:05 GMT
… shape the metastatic breast cancer treatment paradigm, … Unfortunately, ER-positive breast cancer is still considered incurable … letrozole [Femara] and exemestane [Aromasin], and anastrozole [Armidex … advanced-or-metastatic-breast-cancer
FDA approves …
-
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
28 Jul 2025 00:00 GMT
… exemestane.
Unlike HER2-positive and triple-negative breast cancer, … and high-risk breast cancer.
Considering that treatment … breast cancer.
Patients with HR-positive, HER2-negative breast cancer … -positive, HER2-negative breast cancers. Further validation of …
-
Ongoing Research Aims to Alter Management of HR+ Breast Cancer After Frontline CDK4/6 Inhibition
25 Jul 2025 04:20 GMT
… , HER2-negative advanced breast cancer, additional time to … in hormone receptor–positive breast cancer; the clinical implications … option with fulvestrant or exemestane [Aromasin]. Of course, there … hormone receptor–positive breast cancer after progression on …
-
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment
26 Jun 2025 23:48 GMT
… a history of breast cancer. Breast cancer and CVD … anastrozole, exemestane). More than 80% of breast cancers are hormone … in Breast Cancer. Alcohol, tobacco and breast cancer--collaborative … thromboembolism in breast cancer survivors. Breast Cancer Res Treat. …
-
Early Breast Cancer Highlights From ASCO 2025
24 Jun 2025 15:31 GMT
… patients with early HER2-positive breast cancer. Omitting carboplatin yielded comparable pathologic … assessing the benefit of adjuvant exemestane with ovarian function suppression (OFS … adding OFS and switching to exemestane, particularly for higher-risk …
-
Imlunestrant Alone or With Verzenios Improved PROs in Advanced Breast Cancer
03 Jun 2025 01:39 GMT
… ER)–positive, HER2-negative advanced breast cancer who progressed after endocrine therapy … choice between Faslodex (fulvestrant) or Aromasin (exemestane), was also given at the … patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, …
-
PROs Favor Imlunestrant With/Without Abemaciclib in ER+, HER2– Breast Cancer
31 May 2025 20:57 GMT
… ER)–positive, HER2-negative advanced breast cancer who progressed after endocrine therapy … between fulvestrant (Faslodex) or exemestane (Aromasin), was also given at the … patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, …
-
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients
22 May 2025 21:29 GMT
… hormone receptor-positive (HR+) breast cancer,” said Jennifer Schneiders, … the landmark Tamoxifen and Exemestane Trial (TEXT) … + breast cancer.2*
About the Breast Cancer Index Test
The Breast Cancer Index … approvals.
For the Breast Cancer Index Intended Use …
-
Imlunestrant Plus Abemaciclib Provides Consistent Benefit Across Key Subgroups of ER+ Advanced Breast Cancer
15 May 2025 14:37 GMT
… (ER)–positive, HER2-negative advanced breast cancer across clinically and genomically defined … (ET) with fulvestrant (Faslodex) or exemestane. “The combination arm was added … without abemaciclib (abeam) in advanced breast cancer (ABC): a subgroup analysis in …
About
© 1995-2025